Increase the survival of men with hormone-resistant metastatic prostate cancer (mCRPC). This is the goal of already available targeted therapies, which continue to confirm their effectiveness, such as radium-223 dichloride followed by Lutetium-177-PSMA.
Cancer, the cure is increasingly nuclear
by Tiziana Moriconi
December 16, 2021
Lo studio real life
The confirmation comes from a real life study, RALU, whose preliminary results were presented in a poster at the Asco (American Society of Clinical Oncology) congress. This is a retrospective observational study that is evaluating the safety and clinical outcomes of the sequence of the two drugs. The data have been collected from some centers in Germany: for now they concern 49 patients with an average age of the patients was 72 years (57-83), treated with at least one dose of radium-223 and at least one of 177Lu-PSMA. The analysis shows an overall (median) survival of 12.6 months after initiation of 177Lu-PSMA therapy and 31.4 months after initiation of radium-223 dichloride therapy. Furthermore, the therapeutic sequence was well tolerated.
Cancer, the cure is increasingly nuclear
by Tiziana Moriconi
December 16, 2021
“It is encouraging to observe how in real clinical practice (outside clinical studies, ed.), The timely use of radium-223 in prostate cancer patients with mainly bone metastases, followed by 177Lu-PSMA, can optimize the use of available life extension therapies, ”comments Kambiz Rahbar of the nuclear medicine department at the University Hospital Münster, Germany. Which emphasizes a ‘but’: “Real-world insights also show that life-prolonging therapies are underutilized, with the majority of castration-resistant metastatic patients treated with fewer than two therapies. As new treatment options become available, it will be crucial to establish the effective sequence ”.
The “beer belly” (and more) increases the risk for the prostate
at Barbara Orrico
10 Maggio 2022
Radium-223 dichloride
Radium-223 dichloride was the first approved radioligand targeted therapy (TRT) for prostate cancer and is the first and currently only approved alpha targeted therapy that has been shown to prolong the life of mCRPC men with bone metastases. Furthermore, it has been shown to offer significant benefits for quality of life, with a safety profile comparable to placebo. The real-word clinical experience has now exceeded 7 years: globally more than 85,000 men have been treated since its first use.